XML 52 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE (Details 2) (USD $)
3 Months Ended 9 Months Ended 206 Months Ended 0 Months Ended 9 Months Ended 12 Months Ended 0 Months Ended 11 Months Ended 0 Months Ended 9 Months Ended 0 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Apr. 03, 2013
Celgene Corporation
patent
Dec. 14, 2012
Aspire Capital Fund, LLC
Common stock
Sep. 30, 2013
Aspire Capital Fund, LLC
Common stock
Dec. 31, 2012
Aspire Capital Fund, LLC
Common stock
Nov. 14, 2013
Aspire Capital Fund, LLC
Common stock
Subsequent event
Nov. 15, 2013
Aspire Capital Fund, LLC
Common stock
Subsequent event
Dec. 14, 2012
Aspire Capital Fund, LLC
Maximum
Common stock
Mar. 22, 2012
Economic Rights
Sep. 30, 2013
Economic Rights
Dec. 31, 2012
Economic Rights
Mar. 31, 2013
Economic Rights
Celgene Corporation
Apr. 30, 2013
Economic Rights
Celgene Corporation
Feb. 28, 2007
Warrants
Sep. 30, 2013
Warrants
Sep. 30, 2012
Warrants
Sep. 30, 2013
Warrants
Sep. 30, 2012
Warrants
Dec. 31, 2012
Warrants
Sep. 30, 2013
Warrants
Maximum
Dec. 31, 2012
Warrants
Maximum
Reconciliation of the beginning and ending balance of Level 3 inputs                                                
Balance at the beginning of the period                         $ 1,140,000                      
Change in valuation of liability                         (570,000)         0 1,000 0 51,000      
Movement of valuation of liability from Level 3 to Level 2                         (550,000)                      
Balance at the end of the period                         20,000                      
Number of shares issued under purchase agreement           158,982 1,455,787   511,509 1,689,317                            
Purchase price for shares issued under purchase agreement           1,000,000 6,600,000   2,000,000 7,600,000                            
Additional shares committed for sale under agreement                 3,042,038   1,455,787                          
Period of common stock purchase agreement           2 years     2 years                              
Common stock purchase agreement, additional amount committed                 18,000,000   19,000,000                          
Stock issued in lieu of commitment fee           74,548     166,105                              
Stock purchase agreement       423,000       400,000                                
Amount to be paid as percentage of future litigation settlement amount received                       10.00%                        
Number of patents in litigation sold under the definitive agreement         4                                      
One time payment received under the definitive agreement         5,500,000                                      
Amount paid to the holders of liability                               600,000                
Fair value of the liability                           1,100,000                    
Change in fair value of the derivative 63,000 (570,000) (27,000) (547,000)                 600,000                      
Actual amount owed as a percentage of one-time payment received                             10.00%                  
Warrants Liability                                                
Fair value of the warrants                                 $ 6,800,000 $ 0   $ 0   $ 0    
Risk free interest rate (as a percent)                                 4.68%              
Expected volatility (as a percent)                                 85.00%              
Expected dividend yield (as a percent)                                 0.00%              
Contractual life                                 7 years              
Expected term                                             1 year 1 year